The abstract is read at the publisher; the summary is JClub's.
SilencioM markedly reduces tau pathology after a single intracerebroventricular injection in PS19 mice, a model of severe tauopathy, targeting MAPT.
- Why it matters: Tauopathies lack effective treatments, and tau accumulation is central to their pathogenesis, creating a need for precise, safe gene-silencing therapeutics.
- What they did: The study developed SilencioM, an interfering oligonucleotide that targets human, primate, rat, and mouse MAPT orthologs, and tested it in PS19 mice after one intracerebroventricular dose.
- The result: The observed tau-pathology reduction supports SilencioM as a candidate that could move from efficacy work into IND-enabling studies, with straightforward manufacturing and delivery without lipid nanoparticles or lipophilic conjugation.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.